The role of @entity10114 in the management of XXXX and its complications.

@entity1 @entity6 @entity28 @entity2316 @entity73 @entity16 @entity2690 @entity10114 @entity209 @entity413 @entity2241
UNASSIGNED: @entity6 is a chronic @entity209 which is a serious global problem. In 2010 an estimated 285 million @entity1 had @entity6 and within the next 20  years this value is expected to almost double. Many antidiabetic therapies focus on improving @entity2690 sensitivity, increasing @entity2690 production, and/or decreasing the level of blood @entity413 . Although a number of synthetic medicines are available, drugs of natural origin have aroused great interest. @entity10114 seem to demonstrate adequate properties. Many experiments have shown that these compounds have several antidiabetic mechanisms. They can inhibit enzymes involved in @entity413 metabolism, prevent the development of @entity2690 resistance and normalize plasma @entity413 and @entity2690 levels. These natural compounds, in contrast to synthetic drugs, apart from producing a hypoglycemic effect have also been found to manifest hypolipidemic and anti- @entity28 activity. @entity10114 are also promising agents in the prevention of @entity6 complications. They have strong antioxidant activity and inhibit the formation of advanced glycation end products, implicated in the pathogenesis of @entity2316 , @entity2241 , @entity16 or @entity73 . Until now very few clinical studies have been concerned with the application of @entity10114 in treating @entity6 . However, due to their great therapeutic potential, these compounds deserve special attention.
